Agneta Nordberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1122772/publications.pdf

Version: 2024-02-01

368 papers	33,162 citations	4960 84 h-index	4885 168 g-index
383 all docs	383 docs citations	383 times ranked	23584 citing authors

#	Article	IF	Citations
1	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compoundâ€B. Annals of Neurology, 2004, 55, 306-319.	5.3	3,777
2	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
3	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
5	Neuronal nicotinic receptors in the human brain. Progress in Neurobiology, 2000, 61, 75-111.	5.7	695
6	PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 2008, 29, 1456-1465.	3.1	611
7	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006, 129, 2856-2866.	7.6	587
8	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
9	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
10	Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 1998, 9, 246-257.	1.5	419
11	PET imaging of amyloid in Alzheimer's disease. Lancet Neurology, The, 2004, 3, 519-527.	10.2	418
12	Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neuroscience Letters, 1986, 72, 115-120.	2.1	412
13	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	7.9	409
14	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
15	The use of PET in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 78-87.	10.1	368
16	Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by ¹¹C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining ¹¹C-Pittsburgh Compound B and ¹⁸F-FDG. Journal of Nuclear Medicine, 2012, 53, 37-46.	5.0	354
17	Biochemical changes in Dementia disorders of Alzheimer type (AD/SDAT). Neurobiology of Aging, 1983, 4, 261-271.	3.1	303
18	Nicotinic receptor abnormalities of Alzheimerâ€™s disease: therapeutic implications. Biological Psychiatry, 2001, 49, 200-210.	1.3	299

#	Article	IF	Citations
19	Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease. Drug Safety, 1998, 19, 465-480.	3.2	295
20	Decreased protein level of nicotinic receptor Î±7 subunit in the frontal cortex from schizophrenic brain. NeuroReport, 1999, 10, 1779-1782.	1.2	273
21	Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clinical Neurophysiology, 2000, 111, 1817-1824.	1.5	262
22	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
23	Decreased Protein Levels of Nicotinic Receptor Subunits in the Hippocampus and Temporal Cortex of Patients with Alzheimerâ€™s Disease. Journal of Neurochemistry, 2000, 74, 237-243.	3.9	243
24	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 922-936.	7.6	235
25	A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimerâ€™s Disease. primary care companion for CNS disorders, The, 2013, 15, .	0.6	221
26	Tau PET imaging: present and future directions. Molecular Neurodegeneration, 2017, 12, 19.	10.8	220
27	Biological subtypes of Alzheimer disease. Neurology, 2020, 94, 436-448.	1.1	210
28	Brain Activation in Young and Older Adults During Implicit and Explicit Retrieval. Journal of Cognitive Neuroscience, 1997, 9, 378-391.	2.3	207
29	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.1	204
30	Astrocyte Biomarkers in Alzheimerâ€™s Disease. Trends in Molecular Medicine, 2019, 25, 77-95.	6.7	203
31	A critical discussion of the role of neuroimaging in mild cognitive impairment*. Acta Neurologica Scandinavica, 2003, 107, 52-76.	2.1	193
32	Kinetic Analysis of Regional (S)(-)11C-Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission Tomography. Alzheimer Disease and Associated Disorders, 1995, 9, 21-27.	1.3	192
33	Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Molecular Brain Research, 1999, 66, 94-103.	2.3	180
34	Chronic nicotine treatment reduces Î²â€amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Journal of Neurochemistry, 2002, 81, 655-658.	3.9	173
35	A European multicentre PET study of fibrillar amyloid in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	6.4	170
36	Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. Journal of Chemical Neuroanatomy, 2001, 22, 115-126.	2.1	165

#	Article	IF	Citations
37	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.1	161
38	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. Journal of Nuclear Medicine, 2016, 57, 1316-1322.	5.0	161
39	In vivo amyloid imaging with PET in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 100-106.	6.4	154
40	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 2017, 140, aww339.	7.6	153
41	Up-regulation of the inflammatory cytokines IFN-Î³ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. Journal of Neuroimmunology, 2002, 126, 50-57.	2.3	150
42	Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochemistry International, 2003, 43, 243-249.	3.8	147
43	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in alzheimer patients as visualized by positron emission tomography. Neurobiology of Aging, 1992, 13, 747-758.	3.1	145
44	Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behavioural Brain Research, 1993, 57, 255-261.	2.2	145
45	Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Developmental Brain Research, 1998, 108, 147-160.	1.7	145
46	Epibatidine and ABT 418 reveal selective losses of Î±4Î²2 nicotinic receptors in Alzheimer brains. NeuroReport, 1995, 6, 2419-2423.	1.2	142
47	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology, 2012, 79, 229-236.	1.1	138
48	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 198.e1-198.e14.	3.1	135
49	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends in Pharmacological Sciences, 2005, 26, 104-111.	8.7	134
50	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
51	Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. Glia, 2007, 55, 385-399.	4.9	129
52	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimerâ€™s disease. Psychopharmacology, 2006, 188, 509-520.	3.1	128
53	High selective expression of Î±7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Experimental Neurology, 2005, 192, 215-225.	4.1	126
54	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimerâ€™s disease. Brain, 2011, 134, 301-317.	7.6	126

#	Article	IF	Citations
55	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Annals of Neurology, 2008, 63, 621-631.	5.3	124
56	Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2012, 33, 18-28.	1.5	123
57	Nicotine reduces AÎ² in the brain and cerebral vessels of APPsw mice. European Journal of Neuroscience, 2004, 19, 2703-2710.	2.6	122
58	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1119-1132.	6.4	121
59	Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, S12-S18.	1.3	119
60	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	5.7	119
61	Imaging in-vivo tau pathology in Alzheimerâ€™s disease with THK5317 PET in a multimodal paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1686-1699.	6.4	114
62	Postnatal changes of nicotinic acetylcholine receptor Î±2, Î±3, Î±4, Î±7 and Î²2 subunits genes expression in rat brain. International Journal of Developmental Neuroscience, 1998, 16, 507-518.	1.6	113
63	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
64	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain, 2013, 136, 2217-2227.	7.6	111
65	Early astrocytosis in autosomal dominant Alzheimerâ€™s disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
66	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimerâ€™s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimer's Research and Therapy, 2016, 8, 30.	6.2	110
67	Human nicotinic receptorsâ€”Their role in aging and dementia. Neurochemistry International, 1994, 25, 93-97.	3.8	109
68	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108
69	Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Biochemical and Biophysical Research Communications, 1989, 165, 766-771.	2.1	107
70	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
71	Cholinergic receptors in human hippocampus-- regional distribution and variance with age. Life Sciences, 1981, 29, 1937-1944.	4.3	105
72	Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography*. Clinical Pharmacology and Therapeutics, 1995, 57, 309-317.	4.7	104

#	Article	IF	Citations
73	Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal level. Journal of Neural Transmission, 1986, 67, 275-285.	2.8	103
74	Smoking during Pregnancy: A Way to Transfer the Addiction to the Next Generation?. Respiration, 2002, 69, 289-293.	2.6	98
75	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
76	Imaging of Nicotinic and Muscarinic Receptors in Alzheimer's Disease: Effect of Tacrine Treatment. Dementia and Geriatric Cognitive Disorders, 1997, 8, 78-84.	1.5	92
77	Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (Â±)-[]. Brain Research, 1998, 801, 143-149.	2.2	92
78	Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. Journal of Lipid Research, 2011, 52, 1004-1010.	4.2	90
79	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimer's Research and Therapy, 2017, 9, 96.	6.2	90
80	Tacrine and donepezil attenuate the neurotoxic effect of AÎ²(25-35) in rat PC12 cells. NeuroReport, 1998, 9, 1519-1522.	1.2	89
81	Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neuroscience Letters, 1988, 86, 317-321.	2.1	88
82	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease. Behavior Genetics, 1995, 25, 149-159.	2.1	88
83	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimerâ€™s disease dementia. Molecular Psychiatry, 2018, 23, 1666-1673.	7.9	88
84	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12506-12511.	7.1	87
85	Amyloid imaging in Alzheimer??s disease. Current Opinion in Neurology, 2007, 20, 398-402.	3.6	87
86	Glial Asthenia and Functional Paralysis. Neuroscientist, 2015, 21, 552-568.	3.5	87
87	Different Î²-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiology of Aging, 2012, 33, 825.e1-825.e13.	3.1	86
88	Tau positron emission tomography imaging in tauopathies: The added hurdle of offâ€target binding. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 232-236.	2.4	86
89	Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behavioural Brain Research, 2000, 113, 143-157.	2.2	85
90	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	3.1	85

#	Article	IF	Citations
91	Muscarinic receptor compensation in hippocampus of Alzheimer patients. Journal of Neural Transmission, 1983, 56, 13-19.	2.8	84
92	[11C]PIB-amyloid binding and levels of AÎ²40 and AÎ²42 in postmortem brain tissue from Alzheimer patients. Neurochemistry International, 2009, 54, 347-357.	3.8	83
93	Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. Developmental Brain Research, 1991, 63, 201-207.	1.7	79
94	Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients. Current Alzheimer Research, 2009, 6, 4-14.	1.4	75
95	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clinics of North America, 2003, 13, 781-789.	1.0	74
96	Amyloid plaque imaging in vivo: current achievement and future prospects. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 46-50.	6.4	74
97	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1369-1382.	6.4	74
98	Effects of two pyrethroids, bioallethrin and deltamethrin, on subpopulations of muscarinic and nicotinic receptors in the neonatal mouse brain. Toxicology and Applied Pharmacology, 1990, 102, 456-463.	2.8	73
99	Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Research, 1992, 596, 142-148.	2.2	73
100	Long-Term Tacrine Treatment in Three Mild Alzheimer Patients. Alzheimer Disease and Associated Disorders, 1998, 12, 228-237.	1.3	73
101	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
102	Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the Î±7, Î±4 and Î²2 subunits in response to nanomolar concentrations of the Î²-amyloid peptide1â€“42. Neurochemistry International, 2005, 47, 281-290.	3.8	70
103	Astrocyte Biomarkers in Alzheimer Disease. Neurology, 2021, 96, .	1.1	70
104	Comparative Analysis of Nicotine-Like Receptor-Ligand Interactions in Rodent Brain Homogenate. Journal of Neurochemistry, 1985, 45, 24-31.	3.9	69
105	Increased Levels of Tau Protein in SH-SY5Y Cells After Treatment with Cholinesterase Inhibitors and Nicotinic Agonists. Journal of Neurochemistry, 2001, 74, 777-784.	3.9	69
106	Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. ACS Chemical Neuroscience, 2018, 9, 1757-1767.	3.5	69
107	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. Journal of Nuclear Medicine, 2018, 59, 960-966.	5.0	68
108	Clinical studies in Alzheimer patients with positron emission tomography. Behavioural Brain Research, 1993, 57, 215-224.	2.2	67

#	Article	IF	Citations
109	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	3.1	67
110	Amyloid imaging in Alzheimer's disease. Neuropsychologia, 2008, 46, 1636-1641.	1.6	66
111	Coupling of muscarinic receptors to GTP proteins in postmortem human brain â€" alterations in Alzheimer's disease. Neuroscience Letters, 1993, 150, 39-43.	2.1	65
112	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimerâ€™s disease patients and control subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 438-446.	6.4	64
113	The effect of nicotine and cytisine on3H-acetylcholine release from cortical slices of guinea-pig brain. Naunyn-Schmiedeberg's Archives of Pharmacology, 1985, 331, 293-296.	3.0	63
114	Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Research, 1990, 521, 329-332.	2.2	63
115	Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia. Journal of Nuclear Medicine, 2010, 51, 1418-1430.	5.0	63
116	Modulation of Î±7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-Î² Interactions in Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2013, 33, 841-851.	2.6	63
117	Comparison of Early-Phase ¹¹C-Deuterium-l-Deprenyl and ¹¹C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1071-1077.	5.0	63
118	Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiology of Aging, 2008, 29, 168-184.	3.1	61
119	Selective Nicotinic Receptor Consequences in APPSWE Transgenic Mice. Molecular and Cellular Neurosciences, 2002, 20, 354-365.	2.2	60
120	Towards early diagnosis in Alzheimer disease. Nature Reviews Neurology, 2015, 11, 69-70.	10.1	59
121	Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clinical Pharmacology and Therapeutics, 1996, 59, 593-594.	4.7	58
122	Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue. Acta Neuropathologica Communications, 2015, 3, 40.	5.2	58
123	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
124	Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 176-182.	3.0	57
125	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinsonâ€™s disease. Brain Research, 2002, 956, 358-366.	2.2	57
126	Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 30-36.	2.5	57

#	Article	IF	Citations
127	Changes in brain 11Câ€“nicotine binding sites in patients with mild Alzheimerâ€™s disease following rivastigmine treatment as assessed by PET. Psychopharmacology, 2007, 191, 1005-1014.	3.1	57
128	Neuronal Nicotinic Receptor Deficits in Alzheimer Patients with the Swedish Amyloid Precursor Protein 670/671 Mutation. Journal of Neurochemistry, 2008, 72, 1161-1169.	3.9	57
129	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
130	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
131	Chronic fluoride toxicity decreases the number of nicotinic acetylcholine receptors in rat brain. Neurotoxicology and Teratology, 2002, 24, 751-757.	2.4	54
132	3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar Î²-amyloid in Alzheimer brain. Journal of Neuroinflammation, 2013, 10, 90.	7.2	54
133	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
134	Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimerâ€™s patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2120-2126.	6.4	53
135	Unidirectional Influx and Net Accumulation of PIB. Open Neuroimaging Journal, 2008, 2, 114-125.	0.2	53
136	Alzheimerâ€™s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Molecular Psychiatry, 2021, 26, 5888-5898.	7.9	52
137	Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. Neuroscience Letters, 1989, 101, 247-252.	2.1	51
138	Functional Interactions of Fibrillar and Oligomeric Amyloid-Î² with Alpha7 Nicotinic Receptors in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 335-347.	2.6	51
139	Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î±</mml:mi></mml:mrow></mml:math>7 Nicotinic Receptor Drugs. Neural Plasticity, 2015, 2015, 1-13.	2.2	51
140	Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology. Journal of Nuclear Medicine, 2016, 57, 574-581.	5.0	51
141	Effect of long-term nicotine treatment on [3H] nicotine binding sites in the rats brain. Drug and Alcohol Dependence, 1985, 16, 9-17.	3.2	50
142	Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neuroscience Letters, 1998, 254, 85-88.	2.1	50
143	Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiology of Aging, 2011, 32, 2320.e15-2320.e32.	3.1	50
144	Long-term Effects of Galantamine Treatment on Brain Functional Activities as Measured by PET in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2011, 24, 109-123.	2.6	50

#	Article	IF	Citations
145	Neurotrophic and Neuroprotective Actions of (â^')- and (+)-Phenserine, Candidate Drugs for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e54887.	2.5	50
146	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.8	50
147	Synergistic effect of apolipoprotein E Îµ4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenetics and Genomics, 2008, 18, 289-298.	1.5	49
148	The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 380-385.	3.8	49
149	Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicityâ€”a mechanism relating to a damage at the level in post-transcription of the receptor genes. Toxicology, 2004, 200, 169-177.	4.2	48
150	The apolipoprotein E Îµ4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiology of Aging, 2011, 32, 1236-1248.	3.1	48
151	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiology of Aging, 2011, 32, 1388-1399.	3.1	48
152	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2465-2481.	3.1	48
153	Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2013, 33, 929-939.	2.6	48
154	Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid-Î²(1â€“42) Fibril by Molecular Docking and Molecular Dynamics Methods. Journal of Physical Chemistry B, 2015, 119, 11560-11567.	2.6	48
155	Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 38.	6.2	48
156	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimerâ€™s Disease in a Clinical Setting. Journal of Alzheimer's Disease, 2017, 59, 603-614.	2.6	48
157	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. Neurobiology of Aging, 2018, 70, 18-29.	3.1	48
158	Biological markers and the cholinergic hypothesis in Alzheimer's disease. Acta Neurologica Scandinavica, 1992, 85, 54-58.	2.1	47
159	The alpha7 nicotinic receptors in human fetal brain and spinal cord. Journal of Neurochemistry, 2002, 80, 457-465.	3.9	47
160	Regulation of Nicotinic Receptor Subtypes Following Chronic Nicotinic Agonist Exposure in M10 and SH-SY5Y Neuroblastoma Cells. Journal of Neurochemistry, 2002, 70, 2028-2037.	3.9	47
161	Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE Îµ4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiology of Disease, 2006, 24, 326-333.	4.4	47
162	The consequences of reducing expression of the Î±7 nicotinic receptor by RNA interference and of stimulating its activity with an Î±7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochemistry International, 2007, 51, 377-383.	3.8	47

#	Article	IF	Citations
163	Î²-Amyloid 1-42 Oligomers Impair Function of Human Embryonic Stem Cell-Derived Forebrain Cholinergic Neurons. PLoS ONE, 2010, 5, e15600.	2.5	47
164	Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenetics and Genomics, 2009, 19, 635-646.	1.5	46
165	Comparability of [¹⁸F]THK5317 and [¹¹C]PIB blood flow proxy images with [¹⁸F]FDG positron emission tomography in Alzheimerâ€™s disease. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 740-749.	4.3	46
166	Effects of chronic treatment with (+)- and (â^')-nicotine on nicotinic acetylcholine receptors and N-methyl-d-aspartate receptors in rat brain. Brain Research, 1994, 644, 32-39.	2.2	45
167	Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. Journal of Neuroimmunology, 1996, 68, 139-144.	2.3	45
168	Neurotrophic factors promote cholinergic differentiation in human embryonic stem cellâ€derived neurons. Journal of Cellular and Molecular Medicine, 2010, 14, 1476-1484.	3.6	45
169	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. Journal of Neurology, 1994, 242, S12-S15.	3.6	44
170	Cortical laminar tau deposits and activated astrocytes in Alzheimerâ€™s disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography. Scientific Reports, 2017, 7, 45496.	3.3	44
171	The relevance of cerebrospinal fluid Î±-synuclein levels to sporadic and familial Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 130.	5.2	44
172	The competition of (?)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 28-34.	3.0	43
173	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimer's Research and Therapy, 2011, 3, 34.	6.2	43
174	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.8	43
175	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimerâ€™s disease. Journal of Neurochemistry, 2023, 164, 309-324.	3.9	43
176	Chronic nicotine exposure in rat: A behavioural and biochemical study of tolerance. Drug and Alcohol Dependence, 1981, 8, 51-60.	3.2	42
177	Cholinergic activity in hippocampus in chronic alcoholism. Drug and Alcohol Dependence, 1982, 10, 333-344.	3.2	42
178	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.1	42
179	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 348-356.	6.4	41
180	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neuroscience Letters, 1997, 232, 37-40.	2.1	40

#	Article	IF	Citations
181	Spatial Normalization of ¹⁸F-Flutemetamol PET Images Using an Adaptive Principal-Component Template. Journal of Nuclear Medicine, 2019, 60, 285-291.	5.0	40
182	Astroglial tracer BU99008 detects multiple binding sites in Alzheimerâ€™s disease brain. Molecular Psychiatry, 2021, 26, 5833-5847.	7.9	39
183	Distribution of nicotinic receptors in human thalamus as visualized by3H- nicotine and3H-acetylcholine receptor autoradiography. Journal of Neural Transmission, 1988, 73, 77-83.	2.8	38
184	Influence of development and aging on nicotinic receptor subtypes in rodent brain. International Journal of Developmental Neuroscience, 1990, 8, 715-721.	1.6	38
185	Effect of Nicotine on Passive Avoidance Behaviour and Motoric Activity in Mice. Acta Pharmacologica Et Toxicologica, 1985, 56, 337-441.	0.0	38
186	Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 1077-1088.	2.6	38
187	Quantitative positron emission tomography in brain research. Brain Research, 2017, 1670, 220-234.	2.2	38
188	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1276-1286.	6.4	38
189	Tacrine interacts with an allosteric activator site on Î±4Î²2 nAChRs in M10 cells. NeuroReport, 1996, 7, 2201-2205.	1.2	37
190	Higher expression of Î±7 nicotinic acetylcholine receptors in human fetal compared to adult brain. Developmental Brain Research, 2003, 142, 151-160.	1.7	37
191	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
192	Regional [3H]acetylcholine and [3H]nicotine binding in developing mouse brain. International Journal of Developmental Neuroscience, 1985, 3, 667-671.	1.6	36
193	Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1605-1617.	6.4	36
194	Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid-Î² Levels. PLoS ONE, 2013, 8, e58752.	2.5	36
195	The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. Journal of Physical Chemistry Letters, 2016, 7, 3313-3321.	4.6	35
196	Expression of nicotinic acetylcholine receptors in human and rat adrenal medulla. Life Sciences, 2001, 70, 577-590.	4.3	34
197	Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. Journal of Neuroscience Research, 2001, 66, 551-558.	2.9	34
198	Amyloid-Î² peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAÎ²ACs. Brain, 2016, 139, 174-192.	7.6	34

#	Article	IF	Citations
199	Imaging Î²-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 362-373.	6.4	34
200	Effect of Sodium Pentobarbital on the Apparent Turnover of Acetylcholine in Different Brain Regions. Acta Physiologica Scandinavica, 1977, 99, 336-344.	2.2	33
201	Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. Neuroscience Letters, 1986, 70, 160-164.	2.1	33
202	Regulation of Î±4Î²2 nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. NeuroReport, 1995, 6, 313-317.	1.2	33
203	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	6.4	33
204	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimerâ€™s Brain Tissue. Journal of Alzheimer's Disease, 2021, 80, 1723-1737.	2.6	33
205	Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzymeâ€”A plausible missing link for their association with incidence of dementia. Alzheimer's and Dementia, 2020, 16, 1031-1042.	0.8	32
206	Subchronic treatment of rats with nicotine: Effects on tolerance and on [3H]acetylcholine and [3H]nicotine binding in the brain. Drug and Alcohol Dependence, 1986, 17, 37-45.	3.2	31
207	Effect of Huprine X on Î²-Amyloid, Synaptophysin and Î±7 Neuronal Nicotinic Acetylcholine Receptors in the Brain of 3xTg-AD and APPswe Transgenic Mice. Neurodegenerative Diseases, 2010, 7, 379-388.	1.4	31
208	Apolipoprotein Îµ4 Modulates Phenotype of Butyrylcholinesterase in CSF of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 443-458.	2.6	31
209	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 419-430.	0.8	31
210	Muscarinic binding sites in small homogenates and in autoradiographic sections from rat and human spinal cord. Brain Research, 1984, 300, 327-333.	2.2	30
211	In Vivo Detection of Neurotransmitter Changes in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1993, 695, 27-33.	3.8	30
212	In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11C]MPA compared with [11C]ABT-418 and (S)(â^')[11C]nicotine in Rhesus monkeys. Nuclear Medicine and Biology, 1999, 26, 633-640.	0.6	30
213	A Follow-Up Study of the Family with the Swedish APP 670/671 Alzheimerâ€™s Disease Mutation. Dementia and Geriatric Cognitive Disorders, 1999, 10, 526-533.	1.5	30
214	Upregulation of Neuronal Nicotinic Receptor Subunits Î±4,Î²2,and Î±7 in Transgenic Mice Overexpressing Human Acetylcholinesterase. Journal of Molecular Neuroscience, 2002, 18, 211-222.	2.3	30
215	Time Course of Glucose Metabolism in Relation to Cognitive Performance and Postmortem Neuropathology in Met146Val PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2011, 24, 495-506.	2.6	30
216	Transgenic Mice as a Model for Alzheimers Disease. Current Alzheimer Research, 2011, 8, 818-831.	1.4	30

#	Article	IF	Citations
217	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1152-1163.	6.4	30
218	Increased number of muscarinic binding sites in brain following chronic barbiturate treatment to rat. Life Sciences, 1980, 26, 231-237.	4.3	29
219	Chronic Ethanol Treatment Decreases [3H]Epibatidine and [3H]Nicotine Binding and Differentially Regulates mRNA Levels of Nicotinic Acetylcholine Receptor Subunits Expressed in M10 and SH-SY5Y Neuroblastoma Cells. Journal of Neurochemistry, 2002, 70, 1134-1142.	3.9	29
220	Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. ACS Chemical Neuroscience, 2020, 11, 900-908.	3.5	29
221	(S)-(-)-[11C]Nicotine Binding Assessed by PET. Alzheimer Disease and Associated Disorders, 1998, 12, 238-246.	1.3	28
222	Biosynthesis of Acetylcholine in Different Brain Regions in vivo Following Alternative Methods of Sacrifice by Microwave Irradiation. Acta Physiologica Scandinavica, 1976, 98, 307-317.	2.2	27
223	Chapter 14 Effect of nicotine on the release of acetylcholine and amino acids in the brain. Progress in Brain Research, 1989, 79, 149-155.	1.4	27
224	Early Diagnosis of Alzheimer Disease With Positron Emission Tomography. Alzheimer Disease and Associated Disorders, 2000, 14, S109-S113.	1.3	27
225	Influence of cholesterol and lovastatin on Î±-form of secreted amyloid precursor protein and expression of Î±7 nicotinic receptor on astrocytes. Neurochemistry International, 2006, 49, 459-465.	3.8	27
226	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
227	Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. Brain Research, 1996, 726, 207-212.	2.2	26
228	Effects of statins on Î±7 nicotinic receptor, cholinesterase and Î±-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochemistry International, 2007, 50, 800-806.	3.8	26
229	Amyloid Imaging in Early Detection of Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2010, 7, 136-138.	1.4	26
230	Promising two-photon probes for in vivo detection of Î² amyloid deposits. Chemical Communications, 2014, 50, 11694-11697.	4.1	25
231	Changes in populations of cholinergic binding sites in brain after chronic exposure to barbital in rats. Brain Research, 1982, 246, 105-112.	2.2	24
232	Tolerance, physical dependence and changes in muscarinic receptor binding sites after chronic ethanol treatment in the rat. Life Sciences, 1982, 31, 277-287.	4.3	24
233	[3H]Acetylcholine nicotinic recognition sites in human brain: Characterization of agonist binding. Neuroscience Letters, 1987, 83, 298-302.	2.1	24
234	Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. Brain Research, 1993, 620, 42-48.	2.2	24

#	Article	IF	Citations
235	Lovastatin stimulates up-regulation of Î±7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the Î±-form of secreted amyloid precursor protein. Journal of Neuroscience Research, 2005, 82, 531-541.	2.9	24
236	Comparison of subtyping methods for neuroimaging studies in Alzheimerâ€™s disease: a call for harmonization. Brain Communications, 2020, 2, fcaa192.	3.3	24
237	Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimerâ€™s Tauopathy. ACS Chemical Neuroscience, 2021, 12, 2437-2447.	3.5	24
238	The regulation in vitro of placental release of human chorionic gonadotropin, placental lactogen, and prolactin: Effects of an adrenergic beta-receptor agonist and antagonist. American Journal of Obstetrics and Gynecology, 1982, 143, 444-450.	1.3	23
239	Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: Possible mechanism involving lipid peroxidation. Journal of Neuroscience Research, 2003, 71, 397-406.	2.9	23
240	REGIONAL BIOSYNTHESIS OF ACETYLCHOLINE IN BRAIN FOLLOWING FORCED ORAL CHRONIC BARBITONE TREATMENT TO RAT. Journal of Neurochemistry, 1979, 32, 371-378.	3.9	22
241	Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. European Journal of Pharmacology, 1990, 186, 301-305.	3.5	22
242	Synthesis and Characterization of Binding of 5-[76Br] Bromo-3-[[2(S)-Azetidinyl]methoxy]pyridine, a Novel Nicotinic Acetylcholine Receptor Ligand, in Rat Brain. Journal of Neurochemistry, 2001, 73, 1264-1272.	3.9	22
243	Selective decreases of nicotinic acetylcholine receptors in PC12 cells exposed to fluoride. Toxicology, 2003, 183, 235-242.	4.2	22
244	Toward an Early Diagnosis and Treatment of Alzheimer's Disease. International Psychogeriatrics, 2003, 15, 223-237.	1.0	22
245	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-Î² positivity. Molecular Psychiatry, 2021, 26, 5864-5874.	7.9	22
246	The strategic biomarker roadmap for the validation of Alzheimerâ€™s diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	6.4	22
247	Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimerâ€™s disease cases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1093-1102.	6.4	22
248	Regional high affinity synaptosomal transport of choline in mouse brain â€” Influence of oxotremorine treatment. Life Sciences, 1978, 23, 937-944.	4.3	21
249	Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile. Journal of Neural Transmission, 1987, 69, 19-32.	2.8	20
250	Pharmacodynamics of Cholinesterase Inhibitors Suggests Add-on Therapy with a Low-Dose Carbamylating Inhibitor in Patients on Long-Term Treatment with Rapidly Reversible Inhibitors. Journal of Alzheimer's Disease, 2014, 39, 423-440.	2.6	20
251	Effect of oxotremorine on endogenous acetylcholine and on uptake and biotransformation of radioactive choline in discrete regions of mouse brain in vivo. Biochemical Pharmacology, 1976, 25, 135-140.	4.4	19
252	Decreased brain weights in rats after long-term barbital treatments. Life Sciences, 1978, 23, 1583-1590.	4.3	19

#	Article	IF	Citations
253	Elevated levels of AÎ²1â€“40 and AÎ²1â€“42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. Neuroscience Letters, 2002, 328, 269-272.	2.1	19
254	EFFECT OF OXOTREMORINE ON THE APPARENT REGIONAL TURNOVER OF ACETYLCHOLINE IN MOUSE BRAIN. Journal of Neurochemistry, 1978, 30, 383-389.	3.9	18
255	In Vitro Evaluation of ¹¹Câ€Labeled (S)â€Nicotine, (S)â€3â€Methylâ€5â€(1â€Methylâ€2â€Pyrrolidinyl)isoxazole, and (R,S)â€1â€Methylâ€2â€(3â€Pyridyl)azetidine as Nicotinic Receptor Ligands for Positron Emission Tomography Studies. Journal of Neurochemistry, 1998, 71, 1750-1760.	3.9	18
256	Characterization of the Brain Î²-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice. Neurodegenerative Diseases, 2011, 8, 352-363.	1.4	18
257	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18
258	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. Brain Connectivity, 2020, 10, 555-565.	1.7	18
259	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. Methods in Molecular Biology, 2018, 1750, 231-251.	0.9	18
260	Neuroprotection in alzheimerâ€™s disease â€” new strategies for treatment. Neurotoxicity Research, 2000, 2, 157-165.	2.7	17
261	Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils. ACS Chemical Neuroscience, 2021, 12, 3487-3496.	3.5	17
262	Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment. Drug and Alcohol Dependence, 1981, 7, 51-61.	3.2	16
263	Acetylcholine synthesizing activity and nicotinic binding sites in rat hind limb muscles during reinnervation. Acta Physiologica Scandinavica, 1982, 116, 429-435.	2.2	16
264	Correlation of oxidative stress and the loss of the nicotinic receptor alpha4 subunit in the temporal cortex of patients with Alzheimer's disease. Neuroscience Letters, 2003, 338, 13-16.	2.1	16
265	Development of [11C]/[3H]THK-5351 â€“ A potential novel carbon-11 tau imaging PET radioligand. Nuclear Medicine and Biology, 2017, 46, 50-53.	0.6	16
266	A new perspective for advanced positron emission tomographyâ€“based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
267	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimerâ€™s disease variants: AÎ²PParc and PSEN1DE9. Molecular Psychiatry, 2021, 26, 5609-5619.	7.9	16
268	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 612-622.	6.4	16
269	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	6.4	16
270	Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. Neuroscience Letters, 2003, 340, 148-152.	2.1	15

#	Article	IF	Citations
271	Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. Progress in Brain Research, 2004, 145, 301-309.	1.4	15
272	Early changes in AÎ² levels in the brain of APPswe transgenic miceâ€"Implication on synaptic density, Î±7 neuronal nicotinic acetylcholine- and N-methyl-d-aspartate receptor levels. Molecular and Cellular Neurosciences, 2005, 30, 218-227.	2.2	15
273	CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2019, 12, 239.	2.9	15
274	Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. Neurochemistry International, 1998, 32, 435-441.	3.8	14
275	Differential changes of nicotinic receptors in the ratbrain following ibotenic acid and 192â€IgG saporin lesionsof the nucleus basalis magnocellularis. International Journal of Developmental Neuroscience, 1998, 16, 661-668.	1.6	14
276	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667.	2.6	14
277	[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5875-5887.	7.9	14
278	In vitro binding of3H-acetylcholine to nicotinic receptors in rodent and human brain. Journal of Neural Transmission, 1987, 69, 3-18.	2.8	13
279	Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. Neuropharmacology, 2004, 47, 558-571.	4.1	13
280	Differential co-expression of nicotinic acetylcholine receptor Î±4 and Î²2 subunit genes in various regions of rat brain. NeuroReport, 1996, 7, 1645-1649.	1.2	12
281	Rats exhibiting acute behavioural tolerance to nicotine have more [125I]Î±-bungarotoxin binding sites in brain than rats not exhibiting tolerance. Behavioural Brain Research, 2000, 113, 105-115.	2.2	12
282	Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. Neurochemistry International, 2004, 45, 1049-1055.	3.8	12
283	Pharmacodynamic Effects of Nicotine and Acetylcholine Biosynthesis in Mouse Brain. Acta Pharmacologica Et Toxicologica, 1983, 52, 341-347.	0.0	12
284	Different interactions of steric isomers of hexobarbital to muscarinic agonist and antagonist binding sites in brain. Brain Research, 1984, 310, 189-192.	2.2	11
285	Influence of lipid peroxidation on the nicotinic acetylcholine receptors in PC12 cells. Neuroscience Letters, 2000, 286, 163-166.	2.1	11
286	Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or overâ€expressing human acetylcholinestrase. International Journal of Developmental Neuroscience, 2004, 22, 545-549.	1.6	11
287	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1492-1506.	6.4	11
288	Molecular imaging of neuroinflammation in Alzheimerâ€™s disease. Clinical and Translational Imaging, 2015, 3, 437-447.	2.1	11

#	Article	IF	Citations
289	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. NeuroImage: Clinical, 2018, 20, 603-610.	2.7	11
290	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	6.2	11
291	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
292	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimerâ€™s disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	6.4	11
293	Temporal studies of the inhibition of voluntary ethanol intake in the rat induced by intermittent ethanol treatment and some long term neurochemical consequences. Drug and Alcohol Dependence, 1991, 28, 129-144.	3.2	10
294	Steady-State Pharmacokinetics of Tacrine in Long-Term Treatment of Alzheimer Patients. Dementia and Geriatric Cognitive Disorders, 1996, 7, 111-117.	1.5	10
295	Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells. Journal of Neuroscience Research, 2007, 85, 504-514.	2.9	10
296	Effect of denervation on acetylcholine synthesizing activity and nicotineâ€like binding sites in rat hind limb muscles. Acta Physiologica Scandinavica, 1982, 114, 345-350.	2.2	9
297	Effect of acute and subchronic nicotine treatment on cortical efflux of [³H]â€<scp>d</scp>â€aspartate and endogenous GABA in freely moving guineaâ€pigs. British Journal of Pharmacology, 1991, 104, 15-20.	5.4	9
298	Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. International Psychogeriatrics, 2006, 18, S3-S16.	1.0	9
299	Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid Î² Fibril. ACS Chemical Neuroscience, 2019, 10, 1783-1790.	3.5	9
300	Application of advanced brain positron emission tomographyâ€“based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
301	Diurnal fluctuation in striatal choline acetyltransferase activity and strain difference in brain protein content of the rat. Acta Physiologica Scandinavica, 1980, 108, 385-388.	2.2	8
302	[³H]muscimol and [³H]quinuclidinyl benzilate binding in rat cortex in the abstinence after longâ€term barbital treatment. Acta Physiologica Scandinavica, 1986, 126, 153-156.	2.2	8
303	Relation between voluntary ethanol intake in rats and changes in striatal muscarinic binding sites seen after induction of stable ethanol intake by an intermittent ethanol treatment. Brain Research, 1988, 474, 189-191.	2.2	8
304	Expression of the Î±7, Î±4 and Î±3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and Î²â€amyloid. International Journal of Developmental Neuroscience, 2006, 24, 269-273.	1.6	8
305	The Future: New Methods of Imaging Exploration in Alzheimer’s Disease. Frontiers of Neurology and Neuroscience, 2009, 24, 47-53.	2.8	8
306	Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies. ACS Chemical Neuroscience, 2017, 8, 2655-2666.	3.5	8

#	Article	IF	Citations
307	Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex. Journal of Neural Transmission, 1988, 72, 11-18.	2.8	7
308	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. Neurobiology of Aging, 2019, 82, 40-47.	3.1	7
309	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. Journal of Alzheimer's Disease, 2015, 47, 691-704.	2.6	7
310	Influence of age on effects induced by intermittent ethanol treatment on the ethanol drinking pattern and related neurochemical changes in the rat. Drug and Alcohol Dependence, 1988, 22, 117-128.	3.2	6
311	Regional Brain Distribution and Binding of the Muscarinic Receptor Agonist CI-979 Studied by Positron Emission Tomography in the Monkey. Dementia and Geriatric Cognitive Disorders, 1997, 8, 259-266.	1.5	6
312	Use of carbon-11 nicotine in PET studies. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 825-826.	2.1	6
313	Apolipoprotein E Îµ4 allele has an impact on vascular reactivity in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2000, 31, 221-231.	3.0	6
314	Feedback Regulation of SREBP and Aromatase in A Î²(25-35)-Supplemented Human Neuroblastoma Cells. Cellular and Molecular Neurobiology, 2006, 26, 225-235.	3.3	6
315	Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the Î±7 nicotinic acetylcholine receptor. Physical Chemistry Chemical Physics, 2016, 18, 28003-28009.	2.8	6
316	Homomeric and Heteromeric AÎ² Species Exist in Human Brain and CSF Regardless of Alzheimerâ€™s Disease Status and Risk Genotype. Frontiers in Molecular Neuroscience, 2019, 12, 176.	2.9	6
317	Development of 11C-Labeled ASEM Analogues for the Detection of Neuronal Nicotinic Acetylcholine Receptors (Î±7-nAChR). ACS Chemical Neuroscience, 2022, 13, 352-362.	3.5	6
318	Description of a European memory clinic cohort undergoing amyloidâ€PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
319	Effect of oxotremorine and sodium pentobarbitone on the pharmacokinetics of intravenous tracer doses of radioactive choline. Journal of Pharmacy and Pharmacology, 2011, 29, 96-98.	2.4	5
320	Molecular Imaging in Sporadic Alzheimer's Disease Populations and Those Genetically at Risk. Neurodegenerative Diseases, 2014, 13, 160-162.	1.4	5
321	The use of amyloid imaging in clinical praxis: a critical review. Clinical and Translational Imaging, 2015, 3, 7-11.	2.1	5
322	Chapter 43 Future prospects of research on central cholinergic mechanisms. Progress in Brain Research, 1990, 84, 415-418.	1.4	4
323	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease. , 0, , 153-164.		4
324	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer?s disease in vivo?. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1540-1543.	6.4	4

#	Article	IF	Citations
325	Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the Î±7 nicotinic acetylcholine receptor. RSC Advances, 2017, 7, 19787-19793.	3.6	4
326	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 103-117.	2.6	4
327	Longâ€Term Effects on Biotransformation of Labelled Choline in Different Parts of the Rat Brain Induced by Single Choline Injections. Basic and Clinical Pharmacology and Toxicology, 1988, 62, 69-73.	0.0	3
328	Interaction of a Muscarinic Cholinergic Agonist on Acetylcholine and Dopamine Receptors in the Monkey Brain Studied with Positron Emission Tomography. Dementia and Geriatric Cognitive Disorders, 2002, 13, 199-204.	1.5	3
329	Modulation of Choline Transport and Acetylcholine Synthesis in Synaptosomes from Different Brain Regions. Acta Pharmacologica Et Toxicologica, 1985, 56, 193-198.	0.0	3
330	Subcortical and Cortical Regions of Amyloid-Î² Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. Journal of Alzheimer's Disease, 2021, 81, 1613-1624.	2.6	3
331	Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. , 2006, , 181-190.		3
332	Atropine modulates changes in striatal muscarinic receptor binding sites in barbital abstinence in the rat. Acta Physiologica Scandinavica, 1982, 115, 369-371.	2.2	2
333	AÎ²(25â€“35) Attenuated SREBP Level in Nuclear Extracts of Serum-Deprived Human Neuroblastoma Cells. Neurochemical Research, 2009, 34, 845-850.	3.3	2
334	[ICâ€Pâ€178]: HEADâ€TOâ€HEAD IN VIVO COMPARISON OF TAUâ€SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [¹¹C]THK5351 VERSUS [¹¹C]PBB3 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P133.	0.8	2
335	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET. NeuroImage: Clinical, 2019, 22, 101681.	2.7	2
336	In silico studies of ASEM analogues targeting Î±7-nAChR and experimental verification. RSC Advances, 2021, 11, 3942-3951.	3.6	2
337	PET Tracers for Beta-Amyloid and Other Proteinopathies. , 2014, , 199-212.		2
338	Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis. Neurology, 2021, 96, 238-238.	1.1	2
339	Chapter 33 New approaches to clinical and postmortem investigations of cholinergic mechanisms. Progress in Brain Research, 1990, 84, 313-320.	1.4	1
340	Apolipoprotein E Ïµ4 allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. Archives of Gerontology and Geriatrics, 1996, 22, 223-232.	3.0	1
341	Preface. Behavioural Brain Research, 2000, 113, 1.	2.2	1
342	7. Pharmacological modulation of transmitter activity in Alzheimer brains - an experimental model. Acta Neurologica Scandinavica, 2009, 82, 17-20.	2.1	1

#	Article	IF	Citations
343	O4-02-05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENICE MICE: A MULTI-TRACER MICROPET STUDY. , 2014, 10, P253-P253.		1
344	[P2â€“366]: HEADâ€TOâ€HEAD IN VIVO COMPARISON OF TAUâ€SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [¹¹C]THK5351 VERSUS [¹¹C]PBB3 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P765.	0.8	1
345	Different patterns of PIB uptake in AD patients. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S666-S666.	4.3	1
346	Nicotinic Receptors as a new Target for Treatment of Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1998, , 463-468.	0.2	1
347	Interview: Imaging in Alzheimerâ€™s Disease. Imaging in Medicine, 2011, 3, 389-392.	0.0	0
348	Imaging and behavior in Parkinsonâ€™s disease: functional imaging. , 0, , 89-96.		0
349	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0
350	P4-254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol. , 2015, 11, P878-P878.		0
351	O4-07-05: 18F-(S).THK5117 as a PET tracer for tau pathology in Alzheimer's disease and non-alzheimer's disease dementia. , 2015, 11, P285-P285.		0
352	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P127-P127.		0
353	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
354	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimerâ€™s disease case. Neurocase, 2015, 21, 738-747.	0.6	0
355	P3â€262: TAU PET Imaging in Nonâ€Alzheimerâ€™S Disease Dementia: a Multimodal Paradigm. Alzheimer's and Dementia, 2016, 12, P932.	0.8	0
356	P1â€306: Association Between in Vivo TAU Deposition Measured Using [18F]THK5317 Pet and Cognitive Functions in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P539.	0.8	0
357	ICâ€Pâ€170: In Vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic AD Brain in Comparison With Sporadic AD Brain Using 3Hâ€PIB, 3Hâ€THK5117 and 3Hâ€Deprenyl. Alzheimer's and Dementia, 2016, 12, P124.	0.8	0
358	ICâ€Pâ€189: TAU PET Imaging in Nonâ€Alzheimerâ€™S Disease Dementia: A Multimodal Paradigm. Alzheimer's and Dementia, 2016, 12, P137.	0.8	0
359	O4-07-03: Longitudinal Changes in Regional Tau Deposition in Alzheimer's Disease and other Tauopathies Measured by [18 F]-TKH5317 Pet in a Multi-Tracer Design. , 2016, 12, P348-P349.		0
360	P1â€105: In vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic Alzheimer's Disease Brain in Comparison With Sporadic Alzheimer's Disease Brain Using 3Hâ€PIB, 3Hâ€THK5117 and 3Hâ€DEPRENYL. Alzheimer's and Dementia, 2016, 12, P442.	0.8	0

#	Article	IF	Citations
361	P4â€349: EARLYâ€PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P1171.	0.8	0
362	[P4â€“274]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. Alzheimer's and Dementia, 2017, 13, P1390.	0.8	0
363	[ICâ€Pâ€016]: INVESTIGATING THE CLINICAL IMPACT OF [¹⁸F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P19.	0.8	0
364	[ICâ€Pâ€189]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. Alzheimer's and Dementia, 2017, 13, P139.	0.8	0
365	[P1â€“357]: INVESTIGATING THE CLINICAL IMPACT OF [¹⁸F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P394.	0.8	0
366	Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation. Advances in Behavioral Biology, 2002, , 183-186.	0.2	0
367	Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S415-S415.	4.3	0
368	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant AÃŸPParc Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 5471-5471.	7.9	0